- Home
- CHNR vs MIRA Comparison
CHNR vs MIRA Comparison
Compare CHNR & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | MIRA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | China | United States |
| Employees | 9 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 33.7M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CHNR | MIRA |
|---|---|---|
| Price | $3.76 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.6K | ★ 261.2K |
| Earning Date | 12-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $0.73 |
| 52 Week High | $8.20 | $2.45 |
Technical Indicators
Market Signals| Indicator | CHNR | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 56.98 |
| Support Level | $3.86 | $1.44 |
| Resistance Level | $4.22 | $1.69 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 18.48 | 57.14 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.